The influence of cisapride and clarithromycin on QT intervals in healthy volunteers

[1]  K. McColl,et al.  Eradication of Helicobacter pylori: an objective assessment of current therapies. , 1997, British journal of clinical pharmacology.

[2]  J. Chapman,et al.  The mechanism of cyclosporine toxicity induced by clarithromycin. , 2003, British journal of clinical pharmacology.

[3]  J. Dunbar,et al.  New patients presenting to their GP with dyspepsia: does Helicobacter pylori eradication minimise the cost of managing these patients? , 1997, International journal of clinical practice.

[4]  A. Andriulli,et al.  Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin‐dependent) diabetes mellitus , 1997, Alimentary pharmacology & therapeutics.

[5]  D. Paar,et al.  Life-threatening interaction between clarithromycin and disopyramide , 1997, The Lancet.

[6]  J. Ruskin,et al.  Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. , 1996, American heart journal.

[7]  J. Maconochie,et al.  The dilemma of the prolonged QT interval in early drug studies. , 1996, British journal of clinical pharmacology.

[8]  M. Lewin,et al.  Cisapride-induced long QT interval. , 1996, The Journal of pediatrics.

[9]  W. A. Murray,et al.  Long QT syndrome during high-dose cisapride. , 1995, Archives of internal medicine.

[10]  S. Wolfe,et al.  Cisapride and torsades de pointes , 1995, The Lancet.

[11]  F. Fraschini,et al.  Clarithromycin Clinical Pharmacokinetics , 1993, Clinical pharmacokinetics.

[12]  D. Zipes,et al.  Torsades de pointes and proarrhythmia , 1993, The Lancet.

[13]  W. Haefeli,et al.  Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes). , 1990, BMJ.

[14]  C. Prakash,et al.  Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. , 1988, Drugs.

[15]  R. Woestenborghs,et al.  Excretion and biotransformation of cisapride in dogs and humans after oral administration. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[16]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .